Two ASX diagnostics companies agree merger terms to create a stronger combined group
Genetic Signatures Limited (ASX: GSS) and Microba Life Sciences Limited (ASX: MAP) have agreed on the principal commercial terms of a proposed merger, following the announcement of merger discussions on 26 August 2026. The transaction will be implemented through a Scheme of Arrangement under which GSS acquires 100% of Microba’s issued shares and options, with Microba shareholders receiving 0.654 new GSS shares for each Microba share held, equating to approximately 469 million new GSS shares subject to finalisation.
The agreed terms follow preliminary merger discussions announced on 25 August 2026, at which point no deal structure, exchange ratio, or financial metrics had been publicly committed, leaving the path to a binding agreement still subject to due diligence and negotiation.
Under the proposed ownership structure, Microba shareholders would hold approximately 67% of the enlarged combined group, with existing GSS shareholders retaining approximately 33%. The combined entity would remain ASX-listed under the code GSS, and the transaction is structured as an all-scrip arrangement, with no cash consideration or new acquisition financing contemplated.
When big ASX news breaks, our subscribers know first
What the combined group looks like
The Proposed Merger would bring together two established Australian diagnostics businesses to create a group with approximately $29.6 million in aggregated FY2026 revenue, approximately $30 million in combined cash and term deposits as at 30 June 2026, around 149 employees, and products distributed to more than 30 countries.
GSS FY2026 financial results showed the company ending the year with $22.1 million in cash, zero debt, and a net loss 30% narrower than the prior year, figures that directly underpin the $30 million combined cash position cited as a merger strength.
The technology profiles of the two companies are complementary rather than overlapping. GSS’s molecular diagnostics platform targets rapid detection of specific pathogens, while Microba’s metagenomic testing focuses on broader gut microbiome profiling. Together, the businesses would create a wider diagnostic offering across gastrointestinal and infectious disease testing.
Combined group at a glance
| Metric | Genetic Signatures | Microba | Combined Group |
|---|---|---|---|
| Equity value (AUD m) | 15.9 | 35.1 | ~51.0 |
| Cash and term deposits (AUD m, 30 Jun 26) | 22.1 | 7.9 | ~30.0 |
| Net assets (AUD m, 30 Jun 26) | 35.7 | 24.4 | 60.1 |
| Revenue FY26 (AUD m) | 14.8 | 14.8 | ~29.6 |
| Employees | ~52 | ~97 | ~149 |
| Countries served | 30+ | AU, UK, EU, US | 30+ |
Why this merger makes strategic sense
Complementary technologies explained
GSS is a specialist molecular diagnostics company built around its patented 3base® technology. Its EasyScreen™ product range detects gastrointestinal and respiratory pathogens and is registered across Australia, Canada, the EU, and the UK, with FDA 510(k) clearance for its GI parasite detection kit. In practical terms, this technology is designed to identify specific infectious agents quickly and accurately within a clinical setting.
Microba operates as a precision microbiome company, delivering clinical gut microbiome testing to healthcare professionals in Australia and the UK. Rather than pinpointing a single pathogen, Microba’s metagenomic testing maps the broader microbial environment of a patient’s gut. Its therapeutics pipeline also includes the Phase 2-ready MAP 315 asset for ulcerative colitis.
For investors, the distinction matters: GSS rapidly answers “which pathogen is present?”, while Microba addresses the broader question of how the overall gut microbiome is functioning. The two approaches address different clinical questions and are therefore additive, providing the combined group with a wider range of diagnostic tools across gastrointestinal and infectious disease testing.
Expanded international distribution
The combined group would establish a broader commercial platform spanning Australia, the United Kingdom, Europe, and the United States. GSS contributes hospital and reference laboratory relationships, international distribution partners, and its existing regulatory approvals across multiple jurisdictions.
Microba adds its clinician networks, established UK operations, and pathology partnerships with Sonic Healthcare and SYNLAB (as well as Invivo Clinical). Both boards have indicated their view that these complementary commercial channels provide opportunities to introduce the combined group’s products to additional customers and markets.
Cost synergies and financial efficiency
Preliminary analysis has identified a minimum of $2.5 to $3.0 million in potential annualised gross cost synergies. The three main identified sources are:
- Consolidation of duplicated listed-company and public-company costs
- Rationalisation of overlapping corporate and administrative functions
- Consolidation of selected infrastructure and professional services expenditure
Beyond these areas, both boards noted that further synergy opportunities may exist across laboratory and manufacturing footprint, procurement and consumables, combined sales and distribution channels, and shared quality, regulatory, and R&D capability. Both boards believe the Proposed Merger may also accelerate the combined group’s pathway towards cashflow breakeven.
It is important to note that the identified synergies are preliminary estimates, not committed savings, and remain subject to further validation, implementation planning, and successful execution.
Governance and next steps
Board composition
The proposed board of the merged entity would comprise six directors, with three nominated by GSS and three nominated by Microba, providing equal representation from both businesses. The final composition of the board and senior management arrangements will be confirmed in the definitive transaction documentation.
Transaction process and conditions
Shareholders in both companies do not need to take any action at this time. The Proposed Merger remains subject to a number of steps, including:
- GSS shareholder approval at a forthcoming Extraordinary General Meeting (EGM)
- Finalisation and execution of the Scheme Implementation Deed
- Completion of the applicable independent expert process for the schemes of arrangement
- Preparation and ASIC approval of a scheme booklet, and court approval to convene scheme meetings
- Microba shareholder and option holder approval at scheme meetings
- Court approval of the proposed scheme of arrangement
- Satisfaction or waiver of all other required conditions
GSS is being advised by AE Advisors (corporate) and Gadens (legal). Microba is being advised by Latimer Partners (corporate) and Thomsons (legal).
Chairs’ perspectives
Both chairs commented on the strategic significance of the Proposed Merger.
Mike Aicher, Chair of Genetic Signatures
“Bringing Microba and Genetic Signatures together would create an exciting opportunity to combine two complementary areas of diagnostic innovation. By bringing our respective technologies, expertise and commercial capabilities together, we have the potential to build a stronger diagnostics platform and accelerate the delivery of new solutions to clinicians and patients globally. We believe this proposed combination provides a compelling foundation for long-term growth and value creation for shareholders.”
Pasquale Rombola, Chair of Microba
“This merger creates a leader in gastrointestinal diagnostics, with broader revenue and customer bases, and a materially stronger balance sheet to meet the significant global opportunity facing the merged group. We look forward to working together with the GSS team to realise that opportunity.”
Ready to Learn More About the Genetic Signatures and Microba Merger?
The proposed all-scrip merger between Genetic Signatures (ASX: GSS) and Microba Life Sciences (ASX: MAP) would create a combined diagnostics group with approximately $29.6 million in aggregated FY2026 revenue, ~$30 million in cash, and a product reach spanning more than 30 countries. The two businesses bring complementary technologies across infectious disease and gut microbiome diagnostics, with preliminary cost synergies of $2.5 to $3.0 million identified.
Investors seeking to understand the full scope of GSS’s molecular diagnostics platform and its strategic positioning ahead of this transformative transaction can explore the Genetic Signatures investor centre for the latest updates, product information, and corporate announcements.